A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment

作     者：Valentina Marotti Yining Xu Cécilia Bohns Michalowski Wunan Zhang Inês Domingues Hafsa Ameraoui Tom G.Moreels Pieter Baatsen Matthias Van Hul Giulio G.Muccioli Patrice D.Cani Mireille Alhouayek Alessio Malfanti Ana Beloqui 

作者机构：UCLouvainUniversit´e catholique de LouvainLouvain Drug Research InstituteAdvanced Drug Delivery and Biomaterials1200 BrusselsBelgium UCLouvainUniversit´e catholique de LouvainLouvain Drug Research InstituteBioanalysis and Pharmacology of Bioactive Lipids1200 BrusselsBelgium UCLouvainUniversit´e catholique de LouvainInstitute of Experimental and Clinical ResearchLaboratory of Hepato-Gastroenterology1200 BrusselsBelgium Cliniques universitaires Saint-LucDepartment of Hepato-GastroenterologyBrusselsBelgium EM-platformVIB Bio Imaging CoreKU LeuvenCampus GasthuisbergHerestraat 493000 LeuvenBelgium UCLouvainUniversit´e catholique de LouvainLouvain Drug Research InstituteMetabolism and Nutrition Group1200 BrusselsBelgium UCLouvainInstitute of Experimental and Clinical Research1200 BrusselsBelgium WEL Research InstituteAvenue Pasteur61300 WavreBelgium 

出 版 物：《Bioactive Materials》 (生物活性材料（英文）)

年 卷 期：2024年第32卷第2期

页      面：206-221页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Belgian F.R.S.-FNRS(Fonds de la recherche scientifique)under grants WELBIO-CR-2022A-02 The Excellence Of Science(EOS:program no.EOS 30770923 and 40007505) supported by the Marie Skłodowska-Curie Actions for an Individual European Fellowship under the European Union’s Horizon 2020 research and innovation program(grant agreement no.887609) by a FRS-FNRS fellowship(grant agreement no.40000747)(Belgium) partially supported by the FRS-FNRS(convention T.0013.19) FRFS-WELBIO,with the support of the Wallon region(under grant agreement WELBIO-CR-2022 S-01) has received funding from the European Research Council(ERC)under the European Union’s Horizon 2020 research and innovation program(grant agreement No.850997-NanoGut) 

主　　题：Nanocarrier GLP-2 Teduglutide KPV Inflammatory bowel disease 

摘      要：Current treatments for inflammatory bowel disease(IBD)treatment consist of anti-inflammatory *** this study,we sought to induce the physiological secretion of glucagon-like peptide 2,a peptide with intestinal growth-promoting activity,via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle *** this end,we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in *** nanocarriers induced(or did not induce)immunosuppression depending on the presence(or absence)of a hyaluronan-KPV *** strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.